Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing

ConferenceTeprotumumabPositive

AI Analysis

Summary

Dr. Raymond Douglas presented research on a six-week teprotumumab dosing regimen designed to protect hearing in thyroid eye disease patients at the ASOPRS conference. The presentation highlights a potential optimization of the FDA-approved TED treatment's safety profile.

Outcome Details

Research presentation on six-week teprotumumab dosing regimen for hearing protection

Importance:3/10

Sentiment:

0.30

teprotumumabthyroid eye diseaseFDA-approved treatmentdosing optimizationhearing protectionophthalmologyASOPRS conference

Related Companies

$AHR

Read the original article

Published by PR Newswire Biotech on October 12, 2026 2:42 PM

Read Original